CD70 Antibody Conjugate Linkers for High Drug Loading Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD70 antibody drug conjugates face challenges with higher drug loads leading to faster clearance and lower maximum tolerated doses, necessitating the development of CD70 antibody drug conjugates that maintain favorable pharmacokinetic properties while allowing for higher drug loading.
Innovation Solution
CD70 antibody drug conjugates are designed with specific Binding units and Linkers that maintain hydrophilic characteristics, enabling higher drug loading and conjugation to hydrophobic drugs, utilizing Linkers with Polar units such as Sugar, PEG, and Carboxyl units to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If higher drug loading is used in CD70 antibody drug conjugates, then more cytotoxic agent can be delivered to target cells, but clearance rate increases and maximum tolerated dose decreases
Solution Approach 1:
The patent applies parameter changes by modifying the hydrophilicity characteristics of the antibody-drug conjugate through specific linker design. The linker contains polar units (sugar, PEG, or carboxyl groups) that increase the overall hydrophilicity of the conjugate, thereby changing the physicochemical parameters to achieve higher drug loading (DAR 4-8) while maintaining favorable clearance rates and pharmacokinetic properties similar to lower loaded species
Solution Approach 2:
The patent employs composite materials by creating a conjugate structure that combines the hydrophobic cytotoxic drug payload with hydrophilic polar units in the linker. This composite approach allows the conjugate to deliver high drug loading while the hydrophilic components prevent aggregation and maintain solubility, thus resolving the contradiction between quantity of drug delivered and pharmacokinetic reliability
2Quantity of substance
If higher drug loading is used in CD70 antibody drug conjugates, then drug delivery capacity increases, but therapeutic index narrows
Solution Approach 1:
The patent changes the hydrophilicity parameter of the conjugate by incorporating polar units in the linker, which allows higher drug loading while maintaining a narrow therapeutic window. The increased hydrophilicity prevents non-specific aggregation and off-target effects, thereby maintaining an acceptable therapeutic index despite the higher payload
3Reliability
If hydrophobic drugs are conjugated to CD70 antibodies, then cytotoxic efficacy increases, but conjugate stability and solubility decrease
Solution Approach 1:
The patent uses the linker with polar units as an intermediary between the hydrophobic cytotoxic drug and the antibody. This intermediary component maintains the hydrophobic drug's cytotoxic efficacy while the polar units in the linker ensure the overall conjugate stability and solubility by preventing aggregation and enhancing aqueous solubility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD70 antibody drug conjugates achieve improved pharmacokinetic properties and therapeutic indices by maintaining hydrophilicity at higher drug loads, enhancing drug delivery to target cells while reducing clearance rates.
Implementation Method 1
CD70 antibody drug conjugates are designed with specific Binding units and Linkers that maintain hydrophilic characteristics, enabling higher drug loading and conjugation to hydrophobic drugs
Data Source
AI summary
The present invention provides conjugates of CD70 antibodies, and/or antigen binding portions thereof, for use in the treatment of cancer and autoimmune disease.